Skip to main content
Total Market Cap: $45,736,508,969 Volume (24h): $826,464,502

GW Pharmaceuticals plc

GW Pharmaceuticals plc (GWPH) logo
Rank 1
About

GW Pharmaceuticals has subsidiaries both in the US and UK. These sites allow the distribution of their plant-derived cannabinoid medication. Founded in 1998, the company has a reputation for developing close partnerships with medical regulatory bodies. They are responsible for producing the world’s first cannabinoid-based medication Sativex, and the FDA-approved CBD medication Epidiolex.

Website
$219.4800
USD
0.00%
Market cap
$6,778,799,142
Total volume
$320,090,471
Shares outstanding
30,885,726
Rank 1
Website
About

GW Pharmaceuticals has subsidiaries both in the US and UK. These sites allow the distribution of their plant-derived cannabinoid medication. Founded in 1998, the company has a reputation for developing close partnerships with medical regulatory bodies. They are responsible for producing the world’s first cannabinoid-based medication Sativex, and the FDA-approved CBD medication Epidiolex.

Markets
Exchange Symbol Volume (24h) Volume (%) Price
Nasdaq
GWPH
$0
0%
$219.4800
Chart
Social media

Share widget

Copy widget code
Subscribe to our newsletter